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A diphtheria toxin resistance 
marker for in vitro and in vivo 
selection of stably transduced 
human cells
Gabriele Picco1,2, Consalvo Petti1,2, Livio Trusolino1,2, Andrea Bertotti1,2 & Enzo Medico1,2
We developed a selectable marker rendering human cells resistant to Diphtheria Toxin (DT). The 
marker (DTR) consists of a primary microRNA sequence engineered to downregulate the ubiquitous 
DPH2 gene, a key enzyme for the biosynthesis of the DT target diphthamide. DTR expression in 
human cells invariably rendered them resistant to DT in vitro, without altering basal cell growth. 
DTR-based selection efficiency and stability were comparable to those of established drug-resistance 
markers. As mice are insensitive to DT, DTR-based selection can be also applied in vivo. Direct 
injection of a GFP-DTR lentiviral vector into human cancer cell-line xenografts and patient-derived 
tumorgrafts implanted in mice, followed by systemic DT administration, yielded tumors entirely 
composed of permanently transduced cells and detectable by imaging systems. This approach 
enabled high-efficiency in vivo selection of xenografted human tumor tissues expressing ectopic 
transgenes, a hitherto unmet need for functional and morphological studies in laboratory animals.
Stable transduction, i.e. permanent integration of exogenous genetic material in the cellular genome, is 
widely employed in basic and applied biomedical research1. In the case of human cells, this is typically 
achieved by transduction with an expression vector encoding resistance proteins for cytotoxic antibiotics 
like G418, puromycin, hygromycin and others. Pharmacologic selection then yields a cell population 
constitutively expressing the resistance marker, plus additional genetic elements of interest. However, 
current drug/marker systems cannot be used for in vivo selection of transduced human cells propa-
gated in animals as xenografts, since the drugs are also lethal for the host animals. This lack of in vivo 
selectable markers is a crucial drawback for patient-derived cancer xenografts (PDXs), which are directly 
propagated from human tumour tissue into immunocompromised mice and for which no procedures 
for in vivo stable transduction have been found to work efficiently2–6. We reasoned that, in principle, 
injection of a viral expression vector into the PDX mass followed by treatment of the mouse with a drug 
exerting species-specific killing activity only on human non-transduced cells would enable selection of 
stably transduced PDXs, for marker studies or for proof-of-concept therapeutic target validation. We 
considered that diphtheria toxin (DT) has the required pharmacological properties: it invariably kills 
human cells7 using the ubiquitously expressed transmembrane heparin-binding EGF-like growth factor 
(HBEGF) as a receptor8, but has no effect on mouse tissues, because the murine Hbegf does not bind 
DT9,10. Moreover, DT has been successfully employed for cell lineage ablation in animal models10,11. 
A well-documented strategy to induce DT resistance in human cells is the blockade of Diphthamide 
Biosynthesis Protein 2 (DPH2), either by expression of a dominant-negative protein12 or by gene inac-
tivation via insertional mutagenesis13. DPH2 catalyzes a key step in diphthamide biosynthesis, a histi-
dine modification process known to occur only on His715 of Eukaryotic Elongation Factor 2 (EEF2)14. 
After HBEGF-mediated DT internalization, DT inhibits EEF2 by catalyzing the transfer of NAD+ to 
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diphthamide15. In the absence of active DPH2, His715 is not converted to diphthamide and the cell is 
insensitive to DT. Additional genes, including DPH5, DPH6, and DPH7, have been shown to encode 
proteins essential for diphthamide formation and DT-mediated toxicity in human cells16–18. Notably, cells 
lacking diphthamide have no distinct phenotypes except their resistance to DT19. Therefore, the inter-
ruption of diphthamide biosynthesis represents an attractive strategy to render human cells resistant to 
DT without major biological consequences.
To develop a selectable marker conferring resistance to DT, we considered an RNA interference 
approach, using short hairpin sequences inserted into a primary microRNA transcript backbone (shR-
NAmirs). This design adds a Drosha processing site to the hairpin construct that has been shown to 
greatly increase knockdown efficiency20. Four to six different shRNAmir sequences were tested for each 
of the key diphthamide biosynthesis genes.
Results
DPH2 silencing renders human cells resistant to diphtheria toxin in vitro. In principle, to 
kill human cells, diphtheria toxin requires the presence on the cell surface of its receptor, HBEGF, 
and of diphthamide biosintesis proteins, in particular of DPH2. We therefore evaluated HBEGF and 
DPH2 expression in a series of gene expression datasets: (i) 151 CRC cancer cell lines21, (ii) 515 CRC 
PDX (manuscript in preparation), and (iii) expression data for colorectal, glioblastoma, head and neck 
and pancreatic cancer obtained from The Cancer Genome Atlas via the CBioPortal22. As reported in 
Supplementary Fig. 1, both HBEGF and DPH2 are well expressed across all datasets.
To validate DT as a selective agent, we verified its activity on a panel of cell lines of different tissue 
origin, expressing variable levels of HBEGF23. DT activity was indeed always high and independent of 
HBEGF expression levels (Supplementary Fig. 2). To assess if silencing of the genes involved in diphth-
amide biosynthesis confers resistance to DT, HCT116 colorectal cancer (CRC) cells, expressing interme-
diate levels of HBEGF, were chosen as a model and transduced with 18 different shRNAmir constructs, 
targeting the DPH2, DPH5, DPH6 and DPH7 transcripts (Supplementary Table 1). Transduced cells 
were then tested for their response to DT (Fig.  1a) and for downregulation of the target transcript 
(Supplementary Table 2). Among all the tested shRNAmirs, only the construct #4, targeting DPH2, was 
found to induce both robust downregulation of DPH2 mRNA levels and strong resistance to DT. This 
shRNAmir sequence is hereafter referred to as DTR (“diphtheria toxin resistance”). Efficient downregu-
lation of DPH2 and induction of resistance to DT was confirmed in three additional human cancer cell 
lines derived from different tissues and in a non-transformed human breast epithelial cell line (Fig. 1b, 
Supplementary Table 2). Notably, cells expressing the DTR marker were not impaired in their growth 
rate (Supplementary Fig. 3). To assess if DTR can be efficiently employed as a selectable marker in vitro, 
we exploited the expression cassette for GFP and puromycin resistance included in the lentiviral DTR 
vector. HCT116 were transduced with DTR at low MOI to obtain around 2% of GFP-positive (GFP+ ) 
cells, and then selected in the presence of either DT (10 ng/ml) or puromycin (2 ng/ml) for two weeks. 
Both selections were found to strongly increase the GFP+ fraction (> 95%; Supplementary Fig. 3). To 
verify the stability of the resistant phenotype, both selected populations were grown in the absence of DT 
or puromycin for one month, and found to retain a very high fraction of GFP+ cells (~80% and ~90% 
for puromycin and DT-selected cells, respectively; Supplementary Fig. 4). Persistence of the high GFP+ 
fraction was also observed after multiple freeze-thaw cycles (not shown).
Human cells transduced with DTR become resistant to diphtheria toxin in vivo. To assess 
if DTR-transduced cells maintain DT resistance also in the context of a living organism, HCT116 cells 
transduced with DTR or with a control vector were grown as subcutaneous xenografts in nude mice. 
When xenografts reached ~50 mm3, mice were treated with DT or with vehicle for three weeks. As 
shown in Fig. 2a, treatment of control HCT116 xenografts with 1 μ g/kg DT strongly reduced their growth 
rate, and 5 μ g/kg DT induced complete tumor regression, which persisted also after DT suspension. 
Conversely, DTR transduced cells resisted to both doses of DT and continued growing in the presence of 
DT and after its withdrawal (Fig. 2b). Notably, in the absence of DT, DTR-transduced HCT116 xenografts 
displayed a growth rate similar to that of control xenografts (Fig. 2a,b, “Vehicle” lines), confirming that 
DTR expression has no major effects on cancer cell growth. As previously reported, no adverse effects 
were observed in mice treated with DT10,24.
To verify the possibility of using DTR as a marker for in vivo selection of transduced cells, we designed 
the experiment illustrated in Fig. 2c. Briefly, GFP-DTR-transduced and control HCT116 cells were mixed 
in a 1:20 ratio, to obtain a heterogeneous population in which the DTR-expressing, GFP+ fraction was 
around 5%. The mixed cell population was then implanted and grown in nude mice xenografts in the 
absence or presence of DT for three weeks, followed by two additional weeks without treatment. As 
shown in Fig. 2d, treatment with 5 μ g/kg DT did not induce tumor regression but only a reduced growth 
rate. After two weeks from the end of the treatment, flow cytometry on the explanted tumors revealed a 
striking enrichment of GFP+ cells in the DT-treated arm (Fig. 2d). Altogether, these results show that 
DPH2 silencing by DTR confers resistance to DT also in vivo and can be exploited for in vivo selection 
of transduced cells.
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In vivo transduction and selection for DTR expression in xenografts from human cell lines 
and tumors. Generation of genetically modified xenografts is easily accomplishable with most neo-
plastic cell lines by in vitro transduction and selection, followed by implant in mice. In the case of PDXs 
however, such procedure is typically not applicable or poorly efficient. We therefore sought to verify if 
direct intratumoral injection of the DTR vector in xenografts from human cell lines and patient-derived 
tumors, followed by DT treatment of mice, could lead to the development of xenografts significantly 
enriched in transduced cells. To this aim, HCT116 xenografts in nude mice were directly transduced by 
intratumoral injection of concentrated lentiviral particles of GFP-DTR or GFP-control (scramble) vector. 
After one week, cell suspensions were obtained from a first set of transduced tumors for flow cytometry 
analysis, which detected a fraction of GFP+ cells around 1% for both vector types (average of 5 meas-
urements = 0.97% +/− 1.70%). In a parallel set of xenografts, one week after transduction, mice were 
treated with DT for three weeks, followed by two weeks of suspension, after which DT was maintained 
until tumor explant (Fig.  3a). While all tumors displayed marked shrinkage after three weeks of DT 
treatment, only DTR-transduced tumors resumed growth after the initial shrinkage. The regrown tum-
ors featured a multinodular mass, suggestive of parallel growth of multiple resistant subclones from the 
areas of vector injection (Fig. 3b, photo insert). GFP-DTR-transduced and selected xenografts revealed a 
striking enrichment in human GFP+ cells with respect to transduced tumors grown in the absence of 
selection (99% vs 3%; Fig. 3b,c).
Intriguingly, the high fraction of transduced cells and the DT resistance were stably maintained over 
multiple passages in mice, also in the absence of DT selective pressure (Supplementary Fig. 5). Moreover, 
growth of GFP-DTR-transduced tumors implanted subcutaneously or in the peritoneum cavity could be 
Figure 1. DPH2 silencing renders human cell lines resistant to DT. (a) Crystal violet staining of HCT116 
cells transduced with Scramble or shRNAmirs targeting DPH2 (sh1-4), DPH5 (sh5-9), DPH6 (sh10-13) 
and DPH7 (sh14-18), grown in the absence or presence of DT (10 ng/ml) for one week. The only construct 
conferring resistance to DT was sh4, hence renamed DTR. (b) Crystal violet staining of human normal 
(HME1) and neoplastic cell lines (HCT116, colon; A549, lung; OVCAR4, ovary; SNB19, glioblastoma) 
transduced with Scramble or DTR vector and grown in the absence or presence of DT (1 ng/ml or 10 ng/ml) 
for one week.
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longitudinally followed by measuring in vivo GFP fluorescence signal as a surrogate value of the tumor 
mass volume (Supplementary Fig. 6).
As a proof of concept of the efficiency of the DTR vector system in an additional preclinical platform, 
we reproduced the same experimental procedure employing human CRC PDXs instead of cell line xen-
ografts. A preliminary test confirmed that also these PDX tumors were sensitive to DT, independently of 
their genetic makeup (Supplementary Fig. 7). One CRC PDX model was transduced in vivo by a single 
Figure 2. DTR transduced cells are resistant to DT in vivo. (a,b) Tumor growth curves of xenografts from 
HCT116 cells transduced with either the Scramble vector (a) or the DTR vector (b) in nude mice treated 
with DT (1 μ g/kg or 5 μ g/kg) or vehicle (n = 5). (c) Schema of the in vivo selection experiment. Nude mice 
xenografts obtained from a mixture of DTR-transduced (GFP-positive) and parental (GFP-negative) HCT116 
cells (1:20 ratio) were treated with DT (5 μ g/kg) or vehicle for three weeks. It is expected that xenografts 
grown in the presence of DT are enriched in GFP-positive cells. (d) Tumor growth curves (n = 4) in the 
course of the DT selection process, followed by flow-cytometry analysis of GFP levels in representative 
tumors explanted from unselected (up) and selected (bottom) cohorts, as indicated.
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intratumoral injection of GFP-DTR lentiviral particles. Also in this case transduction efficiency was esti-
mated as above to be around 1%. The DT selection process was then monitored by in vivo tracking of the 
GFP signal in the transduced tumors. To reduce the background due to the white fur, the skin surround-
ing the xenograft was shaved. After about five weeks of selection, the GFP signal became detectable in the 
tumor mass, and kept increasing in the following weeks (Fig. 4a). As confirmed by flow cytometry and 
microscopic analysis, almost all human cancer cells were positive for GFP (Fig. 4b,c). Also in this case 
lentiviral transduction of PDX tumors with GFP-DTR did not alter tumor morphology and proliferative 
index (Ki67 expression; Supplementary Fig. 8) or the expression of differentiation and functional mark-
ers commonly employed for CRC classification (CDK20, CDX2 and b-catenin; Supplementary Fig. 9. In 
Figure 3. In vivo selection of DT transduced tumors. (a) Schema of the in vivo DTR transduction and 
selection experiment. (b) Growth curves of HCT116 xenografts in CD1-nude mice transduced in vivo by 
intratumoral injection of scramble-GFP or DTR-GFP concentrated lentiviral particles. A week after vector 
injection, DT was administered at increasing concentrations for three weeks, followed by 12 days of drug 
withdrawal and two additional weeks of treatment. One control tumor for each vector was allowed to grow 
in the absence of DT as a control. (c,d) Flow cytometry analysis of the fraction of GFP+ cells in unselected 
(c) or DT-selected (d) tumors. (e) Fluorescence micrograph displaying GFP expression in a representative 
DTR-injected, DT-selected HCT116 xenograft subsequently re-implanted and grown in the absence of DT.
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Figure 4. In vivo DTR transduction and selection of CRC patient-derived xenografts. (a) In vivo selection 
of a PDX grown in a NOD-SCID mouse and directly injected (white arrow) with the DTR-GFP lentiviral 
vector, imaged by IVIS. After about five weeks of selection, a GFP-positive area emerges in the tumor mass. 
The xenograft area was shaved to reduce fur-derived background. (b) Flow cytometry analysis for GFP 
and human HLA-APC signals of unselected (left) or DT-selected PDXs (right), explanted at the end of 
the selection period. (c) Fluorescence micrograph displaying GFP expression in unselected (left) and DTR-
injected, DT-selected PDX subsequently re-implanted and grown in the absence of DT (right). (d) IVIS 
imaging of an additional CRC PDX model in vivo injected with DTR-GFP lentiviral particles in a single or 
multiple site (upper and lower panels, respectively) and selected with DT for six weeks. In this model GFP-
positive regions became already detectable after three weeks of selection.
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addition, we found that the fraction of GFP positive cells remains very high (92%) after multiple passages 
of propagation of the transduced PDX in the absence of DT selective pressure (Supplementary Fig. 10).
To further explore the possible impact of DTR transduction and DT selection, we performed global 
mRNA expression profiling of: (i) one CRC PDX before any treatment; (ii) its derivative obtained after 
in vivo DTR transduction and DT selection (“P0”); (iii) three additional PDX derivatives propagated from 
the first DT-selected PDX at different passages (“P1”, “P2” and “P4”), in the absence of DT. In accordance 
with the high GFP+ fraction observed by flow cytometry, downregulation of the DPH2 transcript was 
maintained in all DTR samples respect to the parental PDX, even at four passages after transduction and 
selection (Supplementary Fig. 11a). Correlation analysis revealed that the range of correlations between 
the parental PDX and its DTR derivatives was similar to that of correlations between the various DTR 
derivatives (Supplementary Fig. 11b). Interestingly, hierarchical clustering of all samples (PDX and DTR 
derivatives) based on the global expression profile revealed that P1-P4 DTR samples are even closer to the 
parental PDX than the P0 DTR sample, that probably underwent transient modulation of gene expression 
following cell death and tissue reorganization induced by DT selection (Supplementary Fig. 11c). Overall, 
these results show that no major changes in the global transcriptional profile occurred in the CRC PDX 
after DTR transduction and DT selection.
Efficiency of the DTR selection procedure was confirmed in a second PDX model, transduced with sin-
gle or multiple injections of GFP-DTR lentiviral particles. During DT selection, single or multiple GFP+ 
areas became detectable, reflecting growth of GFP+ cells in proximity of the injection sites (Fig.  4d). 
Also in this case, the selection process therefore led to the formation of a growing GFP+ tumor.
Discussion
In this work we demonstrate that an artificial shRNAmir sequence targeting the DPH2 transcript invari-
ably confers resistance to DT in human cells, and that this sequence can be effectively exploited to select 
permanently transduced human cells both in vitro and in vivo. A major limitation of currently available 
selectable markers is the impossibility to apply any selection process in vivo: the drugs used for selection 
are toxic for all eukaryotic cells and therefore would be lethal if administered to a mouse hosting human 
cells, e.g. a human tumor xenograft. This restriction is not particularly relevant for cell lines, which can 
be transduced and selected in vitro and then implanted or injected into immunocompromised mice. 
It is instead critical for PDXs, for which in vivo viral-mediated transduction has only been successful 
with constructs that directly provide a selective advantage during outgrowth25. Such methodology is 
not suitable for basic tumor marking or for therapeutic proof-of-concept studies in which expression of 
the sequence of interest would be detrimental to cancer cells. Ex vivo transduction strategies, by which 
cells are separated from explanted tissues, transduced and reimplanted, have also been described25,26. 
However, the complexity and low efficiency of this approach pose severe limits to their practical appli-
cation. Moreover, in vitro culture of PDX-derived cancer cells has been shown to deeply and irreversibly 
alter their gene expression profile, and therefore their functional state27. In addition to the possibility of 
in vivo selection, other interesting features characterize DTR as a marker. Typically, a resistance marker 
encodes for a protein capable of rendering transduced cells resistant to a toxic compound. The coding 
sequence for such marker is several hundred nucleotides long, and requires a dedicated promoter or an 
internal ribosome entry site for efficient translation, which substantially increases vector size. This in 
turn reduces the size of additional genetic elements that can be efficiently cloned and transduced28. In 
this respect, the DTR sequence has two major advantages: (i) it is only 320 nucleotides long; (ii) it can 
be directly inserted between the promoter and the coding sequence of interest, or after its stop codon, 
before the polyadenylation site. In this way, the nascent transcript is processed to yield both the mRNA of 
interest and the DTR marker, without the need for additional promoters or internal ribosome entry sites. 
Our results show that this is the case: with DTR inserted downstream from GFP, all DT-selected cells 
displayed strong GFP fluorescence. The high efficiency of DTR is also particularly relevant to tumor het-
erogeneity, which should be preserved as much as possible after DTR transduction and DT selection. We 
noticed that intratumoral injection of high titer DTR lentiviral particles in a PDX generates about 0.2–1% 
of stably transduced cells. Considering that the estimated number of cancer cells in a tumor is about 
108 per cubic centimeter29, we therefore estimate that a typical in vivo transduction of a 200 mm3 PDX 
generates about 1–2 × 105 stably transduced cells, which should allow preserving tumor heterogeneity.
In principle, abrogation of diphthamide biosynthesis could affect the function of the involved protein, 
EEF2, and consequently influence protein translation. However, it is unlikely that interference with the 
diphthamide biosynthetic pathway provokes relevant biological alterations, given that tumor morphology 
and growth rate were not modified in our experiments, in accordance with previous findings19. Moreover, 
the fraction of GFP positive cells remains very high after multiple passages of propagation in the absence 
of DT selective pressure. This confirms that stable expression of DTR does not impair cell growth even 
under the stressful conditions of tumor explant and re-implant. In any case, we cannot exclude that 
off-target activity of DTR could reduce stability or translation of additional mRNAs in transduced cells, 
albeit with no overt consequences on cellular growth, morphology or gene expression profile. In view of 
these considerations, how DPH2 gene silencing and in vivo DT selection could impact on maintenance 
of the biological features and heterogeneity of the tumor should be accurately evaluated in each specific 
experimental setting. Regarding e.g. the employment of DTR-transduced PDX to follow drug response 
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in vivo, possible interactions between DPH2 silencing and drug efficacy must be carefully assessed, in 
particular for drugs affecting protein synthesis.
A straightforward way to render human cells resistant to DT would be to abrogate expression of 
HBEGF, encoding the transmembrane DT receptor. However, due to its mitogenic activity30 and to its 
release as a soluble form after membrane shedding31, its silencing is likely to induce phenotypic changes 
in both transduced and surrounding cells. Similarly, other enzymes required for Dhipthamide formation, 
like DPH1 and DPH3, are not suitable candidates because they have been involved in the regulation of 
cell growth and development32,33. Among the remaining candidate targets, DPH2 was not the only one 
tested in our screening for DT resistance markers: at least four independent shRNAmirs were tested 
against each of the DPH5, DPH6 and DPH7 genes. None of them was capable of inducing detectable DT 
resistance. Indeed, the extent of target mRNA downregulation was quite limited for most of them. These 
results imply that, in principle, alternative and more efficient shRNAmirs targeting the same genes could 
promote DT resistance, or otherwise that downregulation of DPH5, DPH6 and DPH7 brings a selective 
disadvantage to transduced cells.
In vivo stable transduction with GFP/luciferase based vectors enabled by DTR is expected to sig-
nificantly improve the spectrum and performance of tumor-tracking applications. This is particularly 
true for intraperitoneal and other orthotopic models, where caliper measurements are not suitable, and 
fluorescence or bioluminescence imaging represent a cost effective, simple approach. In the case of GFP, 
used in the present work, absorption and/or autofluorescence by animal tissues make monitoring of 
labeled cells in deep locations problematic34. Notwithstanding these limitations, the growth of GFP-DTR 
transduced tumors was effectively monitored by in vivo imaging, even when the xenografts were intra-
peritoneal. This indicates that the DTR selection system enables robust expression of the co-selected 
coding sequences, as confirmed by the high levels of GFP signal detected by flow cytometry and fluo-
rescence microscopy in selected cells and xenografts. Moreover, stable DTR expression allows rapid DT 
re-selection of transduced cells, should their fraction become lower.
Additional possible applications of the DTR module include transduction of PDXs with therapeu-
tically relevant sequences, like cDNAs for proteins modulating drug response, or short RNA hairpins 
interfering with gene expression of undruggable or poorly actionable oncogenic drivers. To this aim, 
development of efficient multi-module expression vectors will be greatly facilitated by the small size and 
pri-miRNA nature of DTR. This will however require careful assessment of possible interferences between 
post-transcriptional processing of DTR and other modules, or between these and viral vector assembly35. 
In light of the rapidly increasing availability and use of PDX models for preclinical experimentation, 
the DTR system presented here offers an unprecedented opportunity for direct genetic manipulation of 
human tumor xenografts.
Methods
Cell culture and reagents. All cell lines were purchased from American Type Culture Collection 
(ATCC). Cell lines were maintained in culture following supplier guidelines. Cells were ordinarily sup-
plemented with FBS at different concentrations, 2 mM L-glutamine, antibiotics (100 U/mL penicillin and 
100 mg/mL streptomycin) and grown in a 37 °C and 5% CO2 air incubator. In particular, HCT-116 and 
A549 cell line were maintained in RPMI-1640 medium, supplemented with 10% FBS. Hutu-80 and HeLa 
cells were maintained in DMEM, supplemented with 10% FBS. HME1 cells were cultured DMEM/F-12 
supplemented with 20 ng/mL EGF, 10 μ g/mL insulin, and 100 μ g/mL hydrocortisone and 10% FBS. 
Proliferation assays were performed seeding 5–15 × 103 cells in 24-well plates or 5 × 104 cells in 6-well 
plate. After 24 hours, medium was replaced adding DT (D0564, Sigma) reconstituted to 0.5 mL with ster-
ile distilled water. After one week of treatments, cells were fixed with a solution of 3% Paraformaldehyde 
plus 1% glucose and then stained with 0.05% Crystal Violet in Distilled Water.
RNA interference. For stable silencing of DPH2 and DPH6 genes, pGIPZ Gene Sets 
(RHS4531-NM_001384 and RHS4430-NM_080650) and pGIPZ-GFP-scrambled-shRNAmir lentiviral 
vectors were purchased from Open Biosystems. For inducible silencing of DPH7 and DPH5, pTRIPZ shRNA 
Gene Sets (RHS4740-NM_138778 and RHS4740-NM_001077395) plus pTRIPZ-scrambled-shRNAmir 
lentiviral vectors were purchased from Open Biosystems. Details of individual clones are reported in 
Supplementary Table 2.
The Open Biosystems protocols were followed for bacterial culture growth and for recombination 
checks. pGIPZ and pTRIPZ plasmids were purified with Miniprep or Maxiprep kits (Qiagen) and 
DNA concentration was measured by Nanodrop 1000. All lentiviral constructs were transfected into 
HEK293T cells plated in a 6-well plate at a density of 5 × 104 cells per well one day prior to transfection, 
using Lipofectamine 2000 (Invitrogene). Supernatants were harvested after 48 hours, filtered through 
a 0.45-μ m filter, and used to infect cells in the presence of 4 μ g/mL of polybrene. Cells were selected 
in 2 μ g/mL puromycin or directly in diphtheria toxin at the indicated doses. For cells transduced with 
inducible pTRIPZ vector, shRNAmir expression was induced adding doxycycline (1 μ g/mL) in to the 
growth medium and RFP fluorescence was assessed by FACS analysis before performing growth assay 
and Q-RT-PCR. For in vivo injection, lentiviral particles obtained from the supernatants of 7 15-cm 
plates of HEK293 cells transfected as previously described36, were concentrated by ultracentrifugation. 
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Concentration of the viral p24 antigen was determined by HIV-1 p24 core profile ELISA (PerkinElmer 
Life Sciences).
Q-RT-PCR and gene expression profiling. Total RNA was extracted using the miRNeasy Mini Kit 
(Qiagen), according to the manufacturer’s protocol. The quantification and quality analysis of RNA was 
performed by Thermo Scientific Nanodrop 1000 and Bioanalyzer 2100 (Agilent). DNA was transcribed 
using iScript RT Super Mix (BioRad) following the manufacturer’s instructions. Q-RT-PCR was per-
formed in triplicate on ABI PRISM 7900HT thermal cycler (Life Technologies) with SYBR green dye. The 
sequences of the primers (Sigma Aldrich) used for gene expression analyses of DPH2, DPH5, DPH6 and 
DPH7 genes are reported in Supplementary Table 3. For gene expression profiling, synthesis of cDNA 
and biotinylated cRNA was performed using the IlluminaTotalPrep RNA Amplification Kit (Ambion), 
according to the manufacturer’s protocol using 500 ng of total RNA. Quality assessment and quantifi-
cation of cRNAs were performed with Agilent RNA kits on Bioanalyzer 2100. Hybridization of cRNAs 
(750 ng) was carried out using Illumina Human 48 k gene chips (Human HT-12 V4 BeadChip). Array 
washing was performed using Illumina High Temp Wash Buffer for 10′ at 55 °C, followed by staining 
using streptavidin-Cy3 dyes (Amersham Biosciences). Probe intensity data were obtained and normal-
ized using the Illumina Genome Studio software (Genome Studio V2011.1) and further processed with 
Excel software. Correlation analysis was based on calculation of the Pearson correlation coefficient using 
all probe signals. Hierarchical clustering of PDX samples using euclidean distance and average linkage 
was performed using the GEDAS software37.
Flow cytometry. GFP expression analysis of in vitro cultured cells was performed by flow cytometry: 
cells were trypsinized, diluted in a 1% paraformalhdeide-2% FBS solution, stained with DAPI (D9542, 
Sigma) and analyzed with FACS flow cytometer (CyAn™ , DAKO).
Explanted tumors were dissected by bistoury and resuspended in collagenase (C5138, Sigma), Trypsin 
and Medium 199 (Sigma), for 30 minutes at 37 °C. After inhibition of tripsine and centrifugation, pel-
lets were washed with HBSS 5% FBS and resuspended in red blood cell lysis buffer (NH4Cl (155 nM), 
KHCO3 (10 mM), 0,1 mM EDTA) for 3 minutes. After incubation with DNAse (5 ug/ml) for 5 minutes at 
37 °C, cells were counted and 10 × 106 cells were stained with human HLA-ABC antibody (555555, BD 
Pharmingen) for 45 min in ice. Subsequently, for flow cytometry analyses, cells were filtered with 40 μ m 
filters and stained with DAPI.
Animal models and live imaging. All animal procedures and care administered were approved by 
the Ethical Commitee of the University of Turin and the Italian Ministry of Health. The methods were 
carried out in accordance with the approved guidelines. Nonobese diabetic/severe combined immunode-
ficient (NOD/SCID) mice and CD-1 nude female mice were purchased from Charles River Laboratories 
(Calco, Italy) and maintained in hyperventilated cages. HCT116 xenografts were established by subcu-
taneous inoculation of 2 × 106 cells into the right posterior flank of 5–6 week-old mice. Tumor size was 
evaluated by caliper measurements and the approximate volume of the mass was calculated using the 
formula (d/2)2 × D/2, where d is the minor tumor axis and D is the major tumor axis. HCT116 secondary 
grafts, employed for in vivo transduction, were obtained starting from material explanted from HCT116 
primary xenograft: tumors were cut into 25 to 30 mm3 pieces and re-implanted in the flank of the mice. 
Each intratumoral injection was performed with approximately 1 mg of lentiviral particles diluted in 
physiological saline solution. Tumor cells were injected subcutaneously into immunodeficient mice as 
described above (2 × 106 cells/mouse). After 2 weeks, mice bearing tumors of approximately 100 mm3 
were selected and were randomly divided into 3 groups of 6 mice each. In vivo transduction experiments 
were conducted injecting vectors expressing the shRNAmir sequences and GFP reporter directly into the 
tumor mass. Single or multiple intratumoral injection of 1 mg of lentiviral particles were performed by 
a 0.5 ml syringe. The same procedure was employed to transduce PDXs, in which injection of lentiviral 
particles was performed when tumors reached approximately 200 mm3. For selection of cell xenografts, 
DT was administered three times a week at the indicated dosages and schedules. For PDX selection, DT 
was administered three times a week (5 μ g/kg) until tumor explant. In vivo quantitative and qualitative 
analysis of GFP expression was performed by using the IVIS® Lumina II imaging and the Living Image 
software version 3.0 (Caliper Life Science). The GFP filter sets in the system include emission filter 
(515–575 nm) and excitation filter (445–490 nm). Images of the mice were generated by setting, respec-
tively, 1.5E9 and 1E10 as minimum and maximum values in the color scale. The ROI measurements were 
individually marked as regions of interest (ROI) in the Living Image software, setting auto ROI detection 
with 20 as auto detection threshold.
Immunohistochemistry and confocal microscopy. To detect GFP expression, explanted tumors 
were fixed by immersion in formalin for 24 hours at 4 °C. Subsequently, the specimens were treated 
with 30% sucrose solution to protect them from cryopreservation, then embedded in Optimal Cutting 
Temperature (OCT) compound (Bio-Optica) and stored at − 80 °C until sectioning. Subsequently, 12 μ m 
thick sections were cut with a cryomicrotome (Leica CM 3050 S) and collected in Superfrost Plus Slides 
(Thermo Scientific). Before staining, microscope slides were treated with PBS to remove OCT and stained 
with DAPI (Sigma). The fluorescent light emitted by Turbo-GFP and DAPI was evaluated on a Leica TCS 
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SP2 AOBS confocal microscope. Images were generated with the LAS AF Leica Application Suite soft-
ware (Leica) at 20X of magnification. For IHC, formalin-fixed, paraffin-embedded tissues explanted from 
PDX were partially sectioned (4 μ m thick) using a microtome. 4-μ m paraffin tissue sections were dried 
in a 37 °C oven overnight. Slides were deparaffinized in xylene and rehydrated through graded alcohol to 
water. Endogenous peroxidase was blocked in 3% hydrogen peroxide for 30 minutes. Microwave antigen 
retrieval was carried out using a microwave oven (750 W for 10 minutes) in 10 mmol/L citrate buffer, 
pH 6.0. Slides were incubated with monoclonal mouse anti-human Ki67 (clone MIB-1; DAKO), rab-
bit monoclonal Anti-Cytokeratin 20 antibody [EPR1622Y] (ab76126), mouse Anti-β -Catenin Clone 14/
Beta-Catenin (BD Transduction Laboratories) (Catalog No. 610154) and rabbit monoclonal Anti-CDX2 
antibody [EPR2764Y] (ab76541) overnight at 4 °C inside a moist chamber. Immunohistochemically 
stained slides, were scanned with a 40× objective.
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